![]() |
市場調查報告書
商品編碼
1494815
2030 年醫用膜市場預測:按材料、技術、應用、最終用戶和地區進行的全球分析Medical Membranes Market Forecasts to 2030 - Global Analysis By Material, Technology, Application, End User and By Geography |
根據Stratistics MRC預測,2024年全球醫用膜市場規模將達40億美元,預計2030年將達到77億美元,預測期內年複合成長率為11.2%。
醫用膜是用於各種醫療應用的專用材料,特別是在醫療保健環境和生物醫學研究中。這些膜是薄的半滲透結構,選擇性地允許某些物質通過,同時阻止其他物質通過。它們旨在執行特定功能,例如醫療設備和程序中的過濾、分離和藥物傳輸。醫用膜用途廣泛,包括治療腎衰竭的血液透析機、心肺體外迴圈機中的血液氧合、藥物和生物液體的過濾以及經皮吸收貼片和植入中的藥物控制釋放。
慢性病增加
慢性疾病如末期腎功能衰竭(ESRD)會導致腎衰竭,需要血液透析機或腹膜透析等腎臟替代治療。以膜為基礎的透析系統依靠特殊的薄膜來過濾血液中的廢物和多餘的水。高血壓和糖尿病等腎臟疾病的危險因素的流行正在推動對透析膜的需求,進而推動市場成長。
先進透析膜高成本
醫療保健提供者和保險公司可能在承擔先進的基於膜的醫療技術的成本方面面臨挑戰,導致患者的自付費用和健康保險費增加。這給家庭預算帶來壓力,並可能影響支付醫療費用的能力,特別是對於需要持續治療的慢性或複雜疾病的患者,從而阻礙市場成長。
對高純度產品的需求不斷成長
對高純度產品不斷成長的需求正在推動膜技術的創新和進步,從而導致選擇性、效率和可靠性更高的膜的開發。製造商正在投資研發工作,設計具有客製化特性的薄膜,以滿足醫療和製藥行業高純度應用的特定要求,從而推動市場成長。
長時間的進程內驗證
廣泛的驗證要求增加了將新膜產品推向市場相關的開發成本。製造商必須投入資源進行驗證研究,獲得監管部門的核准,並確保遵守品質標準和法規,這會增加開發成本,降低利潤率,並減緩市場進入或抑制可能阻礙擴張努力的研發投資。
COVID-19 的影響
世界正在與新冠肺炎 (COVID-19) 大流行作鬥爭,而新冠肺炎 (COVID-19) 正在全球傳播。醫用膜主要應用於醫藥過濾、輸液和無菌過濾、生物人工加工、藥物輸送和血液透析機等領域,由於國家封鎖,這些行業的成長略有下降。在許多國家,由於多個行業,特別是運輸和供應鏈的停擺,經濟陷入低迷。由於封鎖,發展緩慢,需求受到阻礙。在 COVID-19 大流行期間,供需缺口、原料採購中斷和價格波動預計將阻礙化學工業的成長。
聚丙烯(PP)領域預計將在預測期內成為最大的領域
聚丙烯(PP)預計在預測期內需求最高,因為它以其生物相容性而聞名,並且在與活體組織和液體接觸時不太可能引起免疫反應或副作用。這一特性使 PP 成為用於過濾、藥物傳輸和組織工程等應用的醫用膜的有吸引力的材料。此外,PP具有優異的機械性能,能夠適應醫療產業常用的各種滅菌方法,推動了市場成長。
奈米過濾產業預計在預測期內年複合成長率最高
奈米過濾濾膜的孔徑比超過濾濾膜更小,因此可以選擇性地去除小分子,同時允許大分子通過。這種選擇性過濾能力在需要精確分離分子和顆粒的醫療應用中是有利的,例如透析、藥物精製和血漿分餾。
由於人們意識的提高、更好的醫療設施的可用性、創新產品的高採用率以及人口中慢性腎臟病率的增加,預計北美將在預測期內佔據最大的市場佔有率。例如,根據美國國家糖尿病、消化和腎臟疾病研究所2016年的報告,超過661,000名美國患有腎衰竭問題,其中468,000人正在接受透析。
由於亞太地區人口眾多,易患各種慢性病和感染疾病,預計在預測期內將維持最高的年複合成長率。因此,創新技術的引入有望以更低的成本為患者提供更好的解決方案。由於生產設施的增加以滿足最終用戶不斷成長的需求,亞太地區的醫用膜市場正在經歷顯著的成長。例如,Medtronic)於 2014 年在中國開設了一家新的製造工廠,並計劃在中國進行其血液透析機系統產品的大部分製造。
According to Stratistics MRC, the Global Medical Membranes Market is accounted for $4.0 billion in 2024 and is expected to reach $7.7 billion by 2030 growing at a CAGR of 11.2% during the forecast period. Medical membranes are specialized materials used in various medical applications, particularly in healthcare settings and biomedical research. These membranes are thin, semi-permeable structures that selectively allow the passage of certain substances while blocking others. They are designed to perform specific functions such as filtration, separation, or drug delivery in medical devices and procedures. Medical membranes are utilized in a wide range of applications, including hemodialysis for kidney failure treatment, blood oxygenation in cardiopulmonary bypass machines, filtration of pharmaceuticals and biological fluids, and controlled release of drugs in transdermal patches or implants.
Rising prevalence of chronic diseases
Chronic diseases such as end-stage renal disease (ESRD) lead to kidney failure, necessitating renal replacement therapies like hemodialysis or peritoneal dialysis. Membrane-based dialysis systems rely on specialized membranes to filter waste products and excess fluids from the blood. The growing prevalence of conditions like hypertension and diabetes, which are risk factors for kidney disease, drives the demand for dialysis membranes which in turn drive the growth of the market.
High cost of advanced membranes
Healthcare providers and insurers may face challenges in covering the costs of advanced membrane-based medical technologies, leading to higher out-of-pocket expenses for patients or increased healthcare premiums. This can strain household budgets and impact the affordability of medical care, especially for individuals with chronic or complex medical conditions requiring ongoing treatment thus hampering the market growth.
Growing demand for high-purity products
The growing demand for high-purity products drives innovation and advancement in membrane technology, leading to the development of membranes with improved selectivity, efficiency, and reliability. Manufacturers invest in research and development efforts to engineer membranes with tailored properties to meet the specific requirements of high-purity applications in the medical and pharmaceutical industries propel the market growth.
Long in-process validation
Extensive validation requirements add to the development costs associated with bringing new membrane products to market. Manufacturers must allocate resources for conducting validation studies, acquiring regulatory approvals, and ensuring compliance with quality standards and regulations, leading to increased development expenses that may reduce profit margins or deter investment in research and development impeding market entry or expansion efforts.
Covid-19 Impact
The world is battling the contagious COVID-19 pandemic, which has spread across the globe. Medical membrane is primarily used in pharmaceutical filtration, IV Infusion & sterile filtration, bio-artificial processes, drug delivery, and hemodialysis; and as an impact of national lockdown, these sectors were experiencing a slight decline in growth rates. In many countries, the economy has dropped due to the halt of several industries, especially transport and supply chain. Demand for the product has been hindered as there is no development due to the lockdown. The demand-supply gap, disruptions in raw material procurement, and price volatility are expected to hamper the growth of the chemical industry during the COVID-19 pandemic.
The polypropylene (PP) segment is expected to be the largest during the forecast period
The polypropylene (PP) is expected to be the largest during the forecast period as it is known for its biocompatibility, meaning it is unlikely to cause an immune response or adverse reactions when in contact with biological tissues or fluids. This property makes PP an attractive material for medical membranes used in applications such as filtration, drug delivery, and tissue engineering. Moreover it has excellent mechanical properties and ability to compatible with various sterilization methods commonly used in the medical industry drive the growth of the market
The nanofiltration segment is expected to have the highest CAGR during the forecast period
The nanofiltration segment is expected to have the highest CAGR during the forecast period as nanofiltration membranes have smaller pore sizes compared to ultrafiltration membranes, allowing them to selectively remove smaller molecules while allowing the passage of larger ones. This selective filtration capability is advantageous in medical applications where precise separation of molecules or particles is required, such as in dialysis, pharmaceutical purification, and blood plasma fractionation.
North America is projected to hold the largest market share during the forecast period owing to increasing awareness among the people, availability of better medical facilities, high adoption of the innovative products and increasing prevalence of chronic kidney disorder among the population. For instance, according to the National Institute of Diabetes and Digestive and Kidney Disease 2016 report, more than 661,000 Americans were suffering from kidney failure problems and out of these 468,000 individuals were on dialysis.
Asia Pacific is projected to hold the highest CAGR over the forecast period owing to presence of large population prone to various chronic and infectious diseases. Therefore, introduction of innovative techniques are expected to provide better solutions to the patient at the low costs. Medical membrane market is growing at significant rate in the Asia Pacific region, owing to increasing manufacturing facilities to meet increasing demand from end users. For instance, Medtronic opened its new manufacturing facility in China in 2014, in which the company will be focusing most of its hemodialysis system products manufacturing.
Key players in the market
Some of the key players in Medical Membranes market include 3M Company, Abbott, Aethlon Medical, Inc., Agilent Technologies, Inc., Amniox Medical, Asahi Kasei, Danaher Corporation, F. Hoffmann-La Roche Ltd, Hangzhou Cobetter Filtration Equipment, Johnson & Johnson Services, Inc, Koch Membrane Systems, Mann+Hummel, Medtronic, Merck Group, NIPRO, Pall Corporation, Sartorius AG, Siemens, Thermo Fisher Scientific Inc. and W. L. Gore & Associates
In May 2024, 3M expands facility in Valley, Nebraska. The expansion of the plant is expected to create about 40 new jobs. The $67 million investment includes new production lines, equipment and a warehouse, and will help 3M more quickly meet customer demand for the company's personal safety products.
In March 2024, Abbott, Real Madrid and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.
In February 2024, Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices. Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier(R) Blood Filtration System
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.